Assessing vaccine efficacy in the field. Further observations.
about
Polysaccharide vaccines for preventing serogroup A meningococcal meningitisMeasles epidemic from failure to immunizeVaccines Through Centuries: Major Cornerstones of Global HealthMethodological challenges in measuring vaccine effectiveness using population cohorts in low resource settingsLessons and challenges for measles control from unexpected large outbreak, MalawiExtracting key information from historical data to quantify the transmission dynamics of smallpoxPartial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico CityField effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France.Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010-2011: a population-based test-negative case-control study.Age distribution of influenza like illness cases during post-pandemic A(H3N2): comparison with the twelve previous seasons, in France.Implications for registry-based vaccine effectiveness studies from an evaluation of an immunization registry: a cross-sectional study.Estimation of influenza vaccine effectiveness from routine surveillance data.Evaluation of the impact of disease prevention measures: a methodological note on defining incidence rates.Measles case fatality rate in Bihar, India, 2011-12Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in SpainMeasles, mumps, and rubella: monitoring in Switzerland through a sentinel network, 1986-94. Sentinella Arbeitsgemeinschaft.Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria.Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008How to understand the efficacy measurements for enterovirus type 71 vaccine?Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.Outbreak of measles in a highly vaccinated secondary school population.A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy.Effectiveness of 2 doses of varicella vaccine in children.Field seasonal influenza vaccine effectiveness: evaluation of the screening method using different sources of data during the 2010/2011 French influenza seasonApplication of the screening method to monitor influenza vaccine effectiveness among the elderly in GermanyThe long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in ItalyVaccine efficacy and control measures in pertussis.Early estimates of 2014/15 seasonal influenza vaccine effectiveness in preventing influenza-like illness in general practice using the screening method in FranceHerpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.Real-time investigation of measles epidemics with estimate of vaccine efficacyThe complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs.Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design.Estimating influenza vaccine effectiveness in an outbreak when anti-viral medications were used as a control measure.Two-dose varicella vaccine effectiveness and rash severity in outbreaks of varicella among public school studentsAge-specific efficacy of pertussis vaccine during epidemic and non-epidemic periodsPriorities in global measles control: report of an outbreak in N'Djamena, Chad.Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months.
P2860
Q24244832-507FF8B7-C302-42DF-A09A-AE84609E5F03Q24515244-D0AD0444-69F2-41B2-AF93-BE394EAE9771Q26774451-61639F63-965D-4967-965A-8AB008E540EEQ26800157-AF301BC3-384A-4B61-9ED5-2D5D79185067Q30223450-8BD886D9-05D2-4E7F-839E-4A97F31A0BD1Q30228781-1FC033E3-425E-4F22-BD57-B947E2D15477Q30381410-360D6D5A-699A-410A-9A00-012516A79005Q30402693-71B9D841-8EAA-4F4D-AE8E-36E2E101C885Q30404923-9176D94C-7F19-49B9-9AE3-7ED3856D48E1Q30428316-AE81AC71-5360-41A9-8BCD-2D5B32E0D52BQ30431735-5FD98C67-7CA6-46F0-82DC-ECA13656DD9EQ33334661-7F363A3D-0ED6-441F-BE28-5F70BCD8FD0FQ33424462-176AB1AD-AD8E-44E4-99E2-B276C1A540B3Q33592634-7707F47E-4399-418E-8EB7-3D7FCD94B5C7Q33605081-C8F96A96-1C81-48AD-90CF-4E27B12B3E33Q33704652-36C1E1C9-7634-4058-88C2-88BDA108CFF2Q33705723-54A60201-B9BB-4C83-9246-F78F7F01731AQ33791473-FA510417-079E-4828-8C27-CC626D76A0B6Q33908993-A7005A8C-BE29-4AD2-BED9-BD38E8C10ED3Q33931144-DD0A38D2-58A3-4109-A4ED-D8B1A59FCD8DQ34033907-EFBDEA62-1492-40DE-A004-26F9334FC0FCQ34034726-E2AABB4E-649E-46A3-A3F7-908EFFE7B9A0Q34272103-882F36A4-8BED-4BCE-BFA0-E7396567873FQ34454372-EEA5FEE8-9280-4B38-A9BF-730CB56FD857Q34763888-844BE4E0-932D-48BF-95F9-9D59D346B778Q34786909-A98F4595-1C97-41EC-B890-10886A99C268Q35211657-BDF39EC9-848A-4D3C-AA43-DAEE5BCFA3FEQ35224155-4C98E925-A295-434E-82CF-A0628A76A2CEQ35627003-E8B32F86-56C3-46D6-BDF2-1CB2F92DFFE5Q35887298-F72632D6-61D2-43AA-A5F0-17611D99CEEDQ35887721-93E9666E-D468-46D1-B134-69B7A92F2211Q35926328-382CE165-BC16-4A28-B545-B785D36126ABQ36131193-9DD98EFD-C6B0-4FE3-A471-6753F343569FQ36201298-988B2471-7B2E-42D6-9654-EA8D0C1BBCCBQ36245512-62601A64-26A1-4262-93E8-3D8639AA9D3CQ36347591-3878E2FE-1989-4A7F-B3F2-6B12D9409E55Q36358276-8609EA54-8076-4E25-BBA9-780AE10BF3DCQ36503370-AE499EBA-F8AE-4F3D-930B-A4990C5D6152Q36503906-3A451E36-110B-46AA-B04B-044224241EE3Q36503931-95DB0473-E7E3-40BC-8142-05BC9317949A
P2860
Assessing vaccine efficacy in the field. Further observations.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Assessing vaccine efficacy in the field. Further observations.
@en
Assessing vaccine efficacy in the field. Further observations.
@nl
type
label
Assessing vaccine efficacy in the field. Further observations.
@en
Assessing vaccine efficacy in the field. Further observations.
@nl
prefLabel
Assessing vaccine efficacy in the field. Further observations.
@en
Assessing vaccine efficacy in the field. Further observations.
@nl
P1476
Assessing vaccine efficacy in the field. Further observations.
@en
P2093
Bernier RH
P304
P356
10.1093/OXFORDJOURNALS.EPIREV.A036023
P577
1988-01-01T00:00:00Z